第99.1展示文本
|
阿爾凱默斯聯繫方式： |
|
|
對於投資者： |
Sandy Coombs +1 781 609 6377 |
|
對於媒體人員： |
Katie Joyce +1 781 249 8927 |
Alkermes plc報告2024年第三季度財務結果
— 三季度營業收入爲37810萬美元 —
— 專有產品的淨銷售額同比增長約18% —
— 來自持續經營的GAAP淨利潤爲9280萬美元，每股攤薄GAAP收益爲0.56美元 —
— 公司重申2024年的財務預期 —
2024年10月24日都柏林報道 — Alkermes plc （納斯達克:ALKS）今日公佈了2024年第三季度的財務結果。
「我們的第三季度財務業績反映出我們專有商業產品組合的強勁年度增長，並使我們良好地滿足了本年度的戰略、運營和財務優先事項。展望未來，我們相信發展我們的專有商業產品和推進我們的產品管線，特別是ALKS 2680，我們的新穎的、正在研究的奧蕊神經，2受體激動劑，以及其他奧蕊神經開發候選藥物，將成爲股東價值的主要驅動力。我們計劃管理業務，提供顯著的盈利能力和現金流，同時投資這些戰略計劃，」阿爾凱默斯公司首席執行官理查德·波普斯表示。「 2025年有潛力成爲阿爾凱默斯的一個轉型年，我們預計完成即將進行的納爾科雷普型1和納爾科雷普型2的第2階段研究，併爲ALKS 2680的潛在登記研究做準備。具有改變高嗜睡症治療潛力，並在其他症狀領域有廣泛的潛在適用性，奧蕊神經2受體激動劑代表着發展中最令人興奮的新治療類別之一，我們相信是阿爾凱默斯和我們股東的重大機遇。」
重要財務亮點
收入
|
三個月之內結束 2020年9月30日 |
|
九個月結束 2020年9月30日 |
||||||
（以百萬計） |
2024 |
2023 |
|
2024 |
2023 |
||||
總營收 |
$ |
378.1 |
$ |
380.9 |
|
$ |
1,127.6 |
$ |
1,285.9* |
所有專有淨銷售額 |
$ |
273.0 |
$ |
231.8 |
|
$ |
775.8 |
$ |
678.0 |
維維特羅® |
$ |
113.7 |
$ |
99.3 |
|
$ |
323.2 |
$ |
298.0 |
ARISTADA®i |
$ |
84.7 |
$ |
81.8 |
|
$ |
249.6 |
$ |
244.3 |
LYBALVI® |
$ |
74.7 |
$ |
50.7 |
|
$ |
203.1 |
$ |
135.7 |
盈利能力
|
三個月已結束 九月三十日 |
|
九個月已結束 九月三十日 |
||||||
（以百萬計） |
2024 |
2023 |
|
2024 |
2023* |
||||
GAAP 持續經營淨收入 |
$ |
92.8 |
$ |
91.6 |
|
$ |
226.4 |
$ |
358.6 |
已終止業務產生的GAAP淨虧損 |
$ |
(0.4) |
$ |
(43.8) |
|
$ |
(5.8) |
$ |
(115.6) |
GAAP 淨收入 |
$ |
92.4 |
$ |
47.8 |
|
$ |
220.6 |
$ |
243.0 |
|
|
|
|
|
|
|
|
|
|
來自持續經營的非公認會計准則淨收入 |
$ |
121.4 |
$ |
150.4 |
|
$ |
321.0 |
$ |
314.7 |
已終止業務產生的非公認會計准則淨虧損 |
$ |
(0.4) |
$ |
(40.8) |
|
$ |
(5.8) |
$ |
(108.5) |
非公認會計准則淨收益 |
$ |
121.0 |
$ |
109.5 |
|
$ |
315.2 |
$ |
206.2 |
|
|
|
|
|
|
|
|
|
|
來自持續業務的息稅折舊攤銷前利潤 |
$ |
112.3 |
$ |
107.2 |
|
$ |
282.4 |
$ |
413.5 |
已停止業務的息稅折舊攤銷前利潤 |
$ |
(0.5) |
$ |
(44.6) |
|
$ |
(6.9) |
$ |
(121.9) |
EBITDA |
$ |
111.8 |
$ |
62.7 |
|
$ |
275.5 |
$ |
291.5 |
1
由於成功解決與楊森製藥N.V.的仲裁，2023年9月30日結束的九個月內，包括大約19540萬美元的往來版稅（和相關利息），這些款項與美國長效INVEGA®產品的淨銷售有關，這些款項通常應在之前的期間確認。
營業收入亮點
LYBALVI
ARISTADAi
VIVITROL
製造和版稅收入
主要營業費用
有關已終止業務的詳細信息請參見下面的註釋1。
|
三個月已結束 九月三十日 |
|
九個月已結束 九月三十日 |
||||||
（以百萬計） |
2024 |
2023 |
|
2024 |
2023 |
||||
研發費用——持續經營 |
$ |
59.9 |
$ |
64.9 |
|
$ |
187.2 |
$ |
196.9 |
研發費用——已終止的業務 |
$ |
0.5 |
$ |
32.3 |
|
$ |
6.9 |
$ |
94.7 |
|
|
|
|
|
|
|
|
|
|
SG&A 費用 — 持續經營 |
$ |
150.4 |
$ |
156.4 |
|
$ |
498.2 |
$ |
520.0 |
銷售和收購費用 — 已終止的業務 |
$ |
— |
$ |
13.1 |
|
$ |
— |
$ |
29.2 |
資產負債表：
2024年9月30日，公司的現金、現金等價物和總投資爲92780萬美元，相比於2024年6月30日的96250萬美元。截至2024年9月30日，公司的總債務爲28880萬美元。
股份回購計劃
2024年第三季度，公司根據2024年2月授權的股份回購計劃回購了約440萬股公司的普通股，總購買價格爲11560萬美元。截至2024年9月30日，公司仍有20000萬美元（不包括任何費用、佣金或其他相關費用）的計劃餘額。
2
2024年財務預期
阿爾凱默斯重申其對2024年的財務預期，如其2024年2月15日發佈的新聞稿所述。
最近的事件
Notes and Explanations
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
3
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income and EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items. EBITDA represents earnings before interest, tax, depreciation and amortization; earnings include share-based compensation expense.
The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non-GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income and EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income and EBITDA should not be considered measures of the company’s liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including drivers of shareholder value and profitability; and the company’s expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, ALKS 2680 and the company’s other orexin portfolio candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations, including those related to profitability; the unfavorable outcome of arbitration or litigation, including so-called “Paragraph IV” litigation and other patent litigation which may lead to competition from generic drug manufacturers, or other disputes related to the company’s products or products using the company’s proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company’s development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may make adverse decisions regarding the company’s products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be
4
precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2023 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.
(tables follow)
i |
The term “ARISTADA” as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise. |
5
Alkermes plc and Subsidiaries |
|
|||||||
Selected Financial Information (Unaudited) |
|
|||||||
|
|
|
|
|
|
|
||
Condensed Consolidated Statements of Operations - GAAP |
|
Three Months Ended |
|
|
Three Months Ended |
|
||
(In thousands, except per share data) |
|
September 30, 2024 |
|
|
September 30, 2023 |
|
||
Revenues: |
|
|
|
|
|
|
||
Product sales, net |
|
$ |
272,999 |
|
|
$ |
231,822 |
|
Manufacturing and royalty revenues |
|
|
105,144 |
|
|
|
149,113 |
|
Research and development revenue |
|
|
— |
|
|
|
3 |
|
Total Revenues |
|
|
378,143 |
|
|
|
380,938 |
|
Expenses: |
|
|
|
|
|
|
||
Cost of goods manufactured and sold |
|
|
63,099 |
|
|
|
61,498 |
|
Research and development |
|
|
59,892 |
|
|
|
64,878 |
|
Selling, general and administrative |
|
|
150,382 |
|
|
|
156,373 |
|
Amortization of acquired intangible assets |
|
|
14 |
|
|
|
8,995 |
|
Total Expenses |
|
|
273,387 |
|
|
|
291,744 |
|
Operating Income |
|
|
104,756 |
|
|
|
89,194 |
|
Other Income, net: |
|
|
|
|
|
|
||
Interest income |
|
|
10,916 |
|
|
|
9,370 |
|
Interest expense |
|
|
(6,000 |
) |
|
|
(6,006 |
) |
Other income, net |
|
|
558 |
|
|
|
149 |
|
Total Other Income, net |
|
|
5,474 |
|
|
|
3,513 |
|
Income Before Income Taxes |
|
|
110,230 |
|
|
|
92,707 |
|
Income Tax Provision |
|
|
17,435 |
|
|
|
1,153 |
|
Net Income From Continuing Operations |
|
|
92,795 |
|
|
|
91,554 |
|
Loss From Discontinued Operations — Net of Tax |
|
|
(414 |
) |
|
|
(43,796 |
) |
Net Income — GAAP |
|
$ |
92,381 |
|
|
$ |
47,758 |
|
|
|
|
|
|
|
|
||
GAAP Earnings (Loss) Per Ordinary Share - Basic: |
|
|
|
|
|
|
||
From continuing operations |
|
$ |
0.57 |
|
|
$ |
0.55 |
|
From discontinued operations |
|
$ |
(0.00 |
) |
|
$ |
(0.26 |
) |
From net income |
|
$ |
0.57 |
|
|
$ |
0.29 |
|
|
|
|
|
|
|
|
||
GAAP Earnings (Loss) Per Ordinary Share - Diluted: |
|
|
|
|
|
|
||
From continuing operations |
|
$ |
0.56 |
|
|
$ |
0.53 |
|
From discontinued operations |
|
$ |
(0.00 |
) |
|
$ |
(0.25 |
) |
From net income |
|
$ |
0.55 |
|
|
$ |
0.28 |
|
|
|
|
|
|
|
|
||
Weighted Average Number of Ordinary Shares Outstanding: |
|
|
|
|
|
|
||
Basic — GAAP and Non-GAAP |
|
|
163,368 |
|
|
|
166,607 |
|
Diluted — GAAP and Non-GAAP |
|
|
167,025 |
|
|
|
171,903 |
|
Condensed Consolidated Statements of Operations - GAAP (Continued) |
|
Three Months Ended |
|
|
Three Months Ended |
|
||
(In thousands, except per share data) |
|
September 30, 2024 |
|
|
September 30, 2023 |
|
||
An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: |
|
|
|
|
|
|
||
Net Income from Continuing Operations |
|
$ |
92,795 |
|
|
$ |
91,554 |
|
Adjustments: |
|
|
|
|
|
|
||
Depreciation expense |
|
|
6,958 |
|
|
|
8,886 |
|
Amortization expense |
|
|
14 |
|
|
|
8,995 |
|
Interest income |
|
|
(10,916 |
) |
|
|
(9,370 |
) |
Interest expense |
|
|
6,000 |
|
|
|
6,006 |
|
Income tax provision |
|
|
17,435 |
|
|
|
1,153 |
|
EBITDA from Continuing Operations |
|
|
112,286 |
|
|
|
107,224 |
|
EBITDA from Discontinued Operations |
|
|
(481 |
) |
|
|
(44,567 |
) |
EBITDA |
|
$ |
111,805 |
|
|
$ |
62,657 |
|
|
|
|
|
|
|
|
||
An itemized reconciliation between net income from continuing operations on a GAAP basis and non-GAAP net income is as follows: |
|
|
|
|
|
|
||
Net Income from Continuing Operations |
|
$ |
92,795 |
|
|
$ |
91,554 |
|
Adjustments: |
|
|
|
|
|
|
||
Share-based compensation expense |
|
|
22,533 |
|
|
|
21,733 |
|
Depreciation expense |
|
|
6,958 |
|
|
|
8,886 |
|
Amortization expense |
|
|
14 |
|
|
|
8,995 |
|
Non-cash net interest expense |
|
|
114 |
|
|
|
115 |
|
Separation expense |
|
|
206 |
|
|
|
9,640 |
|
Income tax effect related to reconciling items |
|
|
(1,255 |
) |
|
|
3,511 |
|
Restructuring expense |
|
|
— |
|
|
|
5,938 |
|
Non-GAAP Net Income from Continuing Operations |
|
|
121,365 |
|
|
|
150,372 |
|
Non-GAAP Net Loss from Discontinued Operations |
|
|
(414 |
) |
|
|
(40,835 |
) |
Non-GAAP Net Income |
|
$ |
120,951 |
|
|
$ |
109,537 |
|
|
|
|
|
|
|
|
||
Non-GAAP diluted earnings per ordinary share from continuing operations |
|
$ |
0.73 |
|
|
$ |
0.87 |
|
Non-GAAP diluted loss per ordinary share from discontinued operations |
|
$ |
(0.00 |
) |
|
$ |
(0.24 |
) |
Non-GAAP diluted earnings per ordinary share from net income |
|
$ |
0.72 |
|
|
$ |
0.64 |
|
Alkermes plc and Subsidiaries |
|
|||||||
Selected Financial Information (Unaudited) |
|
|||||||
|
|
|
|
|
|
|
||
Condensed Consolidated Statements of Operations - GAAP |
|
Nine Months Ended |
|
|
Nine Months Ended |
|
||
(In thousands, except per share data) |
|
September 30, 2024 |
|
|
September 30, 2023 |
|
||
Revenues: |
|
|
|
|
|
|
||
Product sales, net |
|
$ |
775,808 |
|
|
$ |
678,026 |
|
Manufacturing and royalty revenues |
|
|
351,835 |
|
|
|
607,888 |
|
Research and development revenue |
|
|
3 |
|
|
|
16 |
|
Total Revenues |
|
|
1,127,646 |
|
|
|
1,285,930 |
|
Expenses: |
|
|
|
|
|
|
||
Cost of goods manufactured and sold |
|
|
183,215 |
|
|
|
182,911 |
|
Research and development |
|
|
187,152 |
|
|
|
196,873 |
|
Selling, general and administrative |
|
|
498,244 |
|
|
|
519,962 |
|
Amortization of acquired intangible assets |
|
|
1,087 |
|
|
|
26,693 |
|
Total Expenses |
|
|
869,698 |
|
|
|
926,439 |
|
Operating Income |
|
|
257,948 |
|
|
|
359,491 |
|
Other Income, net: |
|
|
|
|
|
|
||
Interest income |
|
|
31,050 |
|
|
|
21,105 |
|
Interest expense |
|
|
(17,930 |
) |
|
|
(16,978 |
) |
Other income (expense), net |
|
|
2,793 |
|
|
|
(415 |
) |
Total Other Income, net |
|
|
15,913 |
|
|
|
3,712 |
|
Income Before Income Taxes |
|
|
273,861 |
|
|
|
363,203 |
|
Income Tax Provision |
|
|
47,460 |
|
|
|
4,598 |
|
Net Income From Continuing Operations |
|
|
226,401 |
|
|
|
358,605 |
|
Loss From Discontinued Operations — Net of Tax |
|
|
(5,834 |
) |
|
|
(115,627 |
) |
Net Income — GAAP |
|
$ |
220,567 |
|
|
$ |
242,978 |
|
|
|
|
|
|
|
|
||
GAAP Earnings (Loss) Per Ordinary Share - Basic: |
|
|
|
|
|
|
||
From continuing operations |
|
$ |
1.36 |
|
|
$ |
2.16 |
|
From discontinued operations |
|
$ |
(0.04 |
) |
|
$ |
(0.70 |
) |
From net income |
|
$ |
1.32 |
|
|
$ |
1.47 |
|
|
|
|
|
|
|
|
||
GAAP Earnings (Loss) Per Ordinary Share - Diluted: |
|
|
|
|
|
|
||
From continuing operations |
|
$ |
1.33 |
|
|
$ |
2.10 |
|
From discontinued operations |
|
$ |
(0.03 |
) |
|
$ |
(0.68 |
) |
From net income |
|
$ |
1.30 |
|
|
$ |
1.42 |
|
|
|
|
|
|
|
|
||
Weighted Average Number of Ordinary Shares Outstanding: |
|
|
|
|
|
|
||
Basic — GAAP and Non-GAAP |
|
|
166,546 |
|
|
|
165,686 |
|
Diluted — GAAP and Non-GAAP |
|
|
170,196 |
|
|
|
170,747 |
|
Condensed Consolidated Statements of Operations - GAAP (Continued) |
|
Nine Months Ended |
|
|
Nine Months Ended |
|
||
(In thousands, except per share data) |
|
September 30, 2024 |
|
|
September 30, 2023 |
|
||
An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: |
|
|
|
|
|
|
||
Net Income from Continuing Operations |
|
$ |
226,401 |
|
|
$ |
358,605 |
|
Adjustments: |
|
|
|
|
|
|
||
Depreciation expense |
|
|
20,599 |
|
|
|
27,696 |
|
Amortization expense |
|
|
1,087 |
|
|
|
26,693 |
|
Interest income |
|
|
(31,050 |
) |
|
|
(21,105 |
) |
Interest expense |
|
|
17,930 |
|
|
|
16,978 |
|
Income tax provision |
|
|
47,460 |
|
|
|
4,598 |
|
EBITDA from Continuing Operations |
|
|
282,427 |
|
|
|
413,465 |
|
EBITDA from Discontinued Operations |
|
|
(6,910 |
) |
|
|
(121,947 |
) |
EBITDA |
|
$ |
275,517 |
|
|
$ |
291,518 |
|
|
|
|
|
|
|
|
||
An itemized reconciliation between net income from continuing operations on a GAAP basis and non-GAAP net income is as follows: |
|
|
|
|
|
|
||
Net Income from Continuing Operations |
|
$ |
226,401 |
|
|
$ |
358,605 |
|
Adjustments: |
|
|
|
|
|
|
||
Share-based compensation expense |
|
|
75,889 |
|
|
|
69,943 |
|
Depreciation expense |
|
|
20,599 |
|
|
|
27,696 |
|
Amortization expense |
|
|
1,087 |
|
|
|
26,693 |
|
Separation expense |
|
|
1,446 |
|
|
|
19,280 |
|
Income tax effect related to reconciling items |
|
|
(3,316 |
) |
|
|
3,332 |
|
Gain on sale of Athlone manufacturing facility |
|
|
(1,462 |
) |
|
|
— |
|
Restructuring expense |
|
|
— |
|
|
|
5,938 |
|
Final award in the Janssen arbitration (2022 back royalties and interest) |
|
|
— |
|
|
|
(197,092 |
) |
Non-cash net interest expense |
|
|
342 |
|
|
|
346 |
|
Non-GAAP Net Income from Continuing Operations |
|
|
320,986 |
|
|
|
314,741 |
|
Non-GAAP Net Loss from Discontinued Operations |
|
|
(5,834 |
) |
|
|
(108,511 |
) |
Non-GAAP Net Income |
|
$ |
315,152 |
|
|
$ |
206,230 |
|
|
|
|
|
|
|
|
||
Non-GAAP diluted earnings per ordinary share from continuing operations |
|
$ |
1.89 |
|
|
$ |
1.84 |
|
Non-GAAP diluted loss per ordinary share from discontinued operations |
|
$ |
(0.03 |
) |
|
$ |
(0.64 |
) |
Non-GAAP diluted earnings per ordinary share from net income |
|
$ |
1.85 |
|
|
$ |
1.21 |
|
Alkermes plc and Subsidiaries |
|
|||||||
Selected Financial Information (Unaudited) |
|
|||||||
|
|
|
|
|
|
|
||
Condensed Consolidated Balance Sheets |
|
September 30, |
|
|
December 31, |
|
||
(In thousands) |
|
2024 |
|
|
2023 |
|
||
Cash, cash equivalents and total investments |
|
$ |
927,784 |
|
|
$ |
813,378 |
|
Receivables |
|
|
367,211 |
|
|
|
332,477 |
|
Inventory |
|
|
191,087 |
|
|
|
186,406 |
|
Contract assets |
|
|
2,969 |
|
|
|
706 |
|
Prepaid expenses and other current assets |
|
|
94,047 |
|
|
|
98,166 |
|
Property, plant and equipment, net |
|
|
225,422 |
|
|
|
226,943 |
|
Intangible assets, net and goodwill |
|
|
83,931 |
|
|
|
85,018 |
|
Assets held for sale |
|
|
— |
|
|
|
94,260 |
|
Deferred tax assets |
|
|
159,960 |
|
|
|
195,888 |
|
Other assets |
|
|
102,880 |
|
|
|
102,981 |
|
Total Assets |
|
$ |
2,155,291 |
|
|
$ |
2,136,223 |
|
Long-term debt — current portion |
|
$ |
3,000 |
|
|
$ |
3,000 |
|
Other current liabilities |
|
|
450,705 |
|
|
|
512,678 |
|
Long-term debt |
|
|
285,823 |
|
|
|
287,730 |
|
Liabilities from discontinued operations |
|
|
— |
|
|
|
4,542 |
|
Other long-term liabilities |
|
|
123,658 |
|
|
|
125,587 |
|
Total shareholders' equity |
|
|
1,292,105 |
|
|
|
1,202,686 |
|
Total Liabilities and Shareholders' Equity |
|
$ |
2,155,291 |
|
|
$ |
2,136,223 |
|
|
|
|
|
|
|
|
||
Ordinary shares outstanding (in thousands) |
|
|
161,776 |
|
|
|
166,980 |
|
|
|
|
|
|
|
|
||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which the company intends to file in October 2024. |
|
|||||||
Alkermes plc and Subsidiaries |
|
|||||||||||||||
Amounts Included in Discontinued Operations |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(In thousands) |
|
Three Months |
|
|
Three Months |
|
|
Three Months |
|
|
Nine Months |
|
||||
Cost of goods manufactured and sold |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Research and development |
|
|
2,516 |
|
|
|
3,913 |
|
|
|
481 |
|
|
|
6,910 |
|
Selling, general and administrative |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Income tax benefit |
|
|
(396 |
) |
|
|
(613 |
) |
|
|
(67 |
) |
|
|
(1,076 |
) |
Loss from discontinued operations, net of tax |
|
$ |
2,120 |
|
|
$ |
3,300 |
|
|
$ |
414 |
|
|
$ |
5,834 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(In thousands) |
|
Three Months |
|
|
Three Months |
|
|
Three Months |
|
|
Nine Months |
|
||||
Cost of goods manufactured and sold |
|
$ |
11 |
|
|
$ |
11 |
|
|
$ |
11 |
|
|
$ |
33 |
|
Research and development |
|
|
29,867 |
|
|
|
32,563 |
|
|
|
32,262 |
|
|
|
94,692 |
|
Selling, general and administrative |
|
|
6,644 |
|
|
|
9,502 |
|
|
|
13,073 |
|
|
|
29,219 |
|
Income tax benefit |
|
|
(6,727 |
) |
|
|
(40 |
) |
|
|
(1,550 |
) |
|
|
(8,317 |
) |
Loss from discontinued operations, net of tax |
|
$ |
29,795 |
|
|
$ |
42,036 |
|
|
$ |
43,796 |
|
|
$ |
115,627 |
|